Answers are grounded in this paper and cite their sources.
The EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
No takes yet. Share an insight, caveat, or question.
Ludmir et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: